Meet Metsera – we are on a mission to reduce the physical, emotional and economic burdens of #obesity as a driver of diseases. We believe that healthy, sustainable weight loss can be empowering, but there is still a significant unmet need for effective therapies. With our fully integrated approach, we plan to establish a cycle of continuous and responsive innovation for a fast-evolving market. Learn more in our release here:?https://metsera.com/news
关于我们
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
- 网站
-
https://metsera.com/
Metsera的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股